Notice of Proposed Sale · 144
Oramed Pharmaceuticals Inc.
ORMPNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ORAMED PHARMACEUTICALS INC.
- Issuer CIK
- 0001176309
- SEC file number
- 001-35813
- Phone
- 646-844-1164
- Person for whose account securities are to be sold
- Joshua Hexter
- Relationships to issuer
- Officer
- Street
- 1185 AVENUE OF THE AMERICAS
- Street (continued)
- 3RD FLOOR
- City
- New York
- State / country code
- NY
- Postal code
- 10036
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 30,000 | 140,100.00 | 41,597,354 | 10/01/2026 | Nasdaq | Oppenheimer & Co. Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- Oppenheimer & Co. Inc.
- Street
- 85 Broad St.
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 05/01/2023 | Shares issued upon vesting of RSUs | ORAMED PHARMACEUTICALS INC. | 108,000 | N | 05/01/2023 | No consideration, shares issued upon vesting of RSUs |
| Common Stock | 05/01/2023 | Shares issued upon vesting of RSUs | ORAMED PHARMACEUTICALS INC. | 27,000 | N | 05/01/2023 | No consideration, shares issued upon vesting of RSUs |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Joshua Hexter | Common Stock | 07/01/2026 | 137,000 | 611,433.85 |
Seller — prior-sale row 1, entry 1
- Name
- Joshua Hexter
- Street
- 1185 AVENUE OF THE AMERICAS
- Street (continued)
- 3RD FLOOR
- City
- New York
- State / country code
- NY
- Postal code
- 10036
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities are being sold pursuant to a Rule 10b5-1 trading plan adopted on 03/30/2026
Notice signature
- Notice date
- 10/01/2026
- Signed
- Joshua Hexter By: /s/ Netta Cohen Title: Authorized Signatory, Oppenheimer Israel (pursuant to delegation)
- Plan adoption dates
- 03/30/2026
Company context
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) is a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection. Oramed’s Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed is building a diversified active investment portfolio while advancing its refined oral insulin program.